Articles related to Pediatric Hematology/Oncology

A rare case of anti-ER5-mediated hemolytic disease of the fetus and newborn required international sourcing of ultrarare blood products and multiple intrauterine transfusions, highlighting the complexity of managing alloimmunization involving newly recognized high-incidence red blood cell antigens.

A young child with an inherited tumor-predisposition syndrome develops recurrent bilateral visual decline after completing first-line chemotherapy for a radiographically diagnosed optic pathway tumor, requiring reassessment of treatment urgency, systemic options, and surveillance.

In a French retrospective cohort, infants with Ewing sarcoma had favorable long-term survival after age-adjusted chemotherapy and predominantly surgical local control, although the 17-patient sample limits conclusions about treatment intensity and late toxicity.

Among 90 pediatric patients with relapsed or refractory B-cell precursor ALL, prior blinatumomab was associated with more relapses at atypical extramedullary sites. The retrospective single-center findings require prospective confirmation.

The FDA expanded approval of the CRISPR-based gene therapy Casgevy to include patients as young as 2 years with sickle cell disease or transfusion-dependent beta thalassemia. The decision was supported by pediatric phase 3 data demonstrating sustained reductions in disease burden.

FcγRIII-mediated macrophage phagocytosis emerges as the dominant mechanism of platelet destruction in FNAIT, suggesting targeted receptor blockade could offer a future therapeutic approach, though evidence remains preclinical.